Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of 18F-FDHT PET/CT as an early treatment response marker in metastasized castration-resistant prostate cancer treated with enzalutamide
2012-005431-86Phase 3Active
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by University Medical Center Groningen. Started Jun 2013; status: active.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2012-005431-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005431-86.